中国医药科学2025，Vol.15Issue(5)：124-127,4.DOI:10.20116/j.issn2095-0616.2025.05.29
吡咯替尼、多西他赛和曲妥珠单抗联合治疗HER2阳性晚期乳腺癌的临床效果及安全性评价
Clinical efficacy and safety evaluation of the combination of pyrrolitinib,docetaxel and trastuzumab for HER2-positive advanced breast cancer
摘要
Abstract
Objective To investigate the effect of the combination of pivotalinib,docetaxel,and trastuzumab in the treatment of human epidermal growth factor receptor-2(HER2)positive advanced breast cancer.Methods A total of 56 patients with HER2-positive advanced breast cancer from May 2020 to May 2024 were retrospectively analyzed.There were 28 cases in the control group treated with docetaxel+trastuzumab and 28 cases in the observation group treated with pyrrotinib+docetaxel+trastuzumab.Short-term clinical efficacy,tumor markers,inflammatory factors and adverse reactions were compared.Results After treatment,the objective remission rate and disease control rate of the observation group were higher than those of the control group,and the difference was statistically significant(P<0.05).Tumor markers in both groups were decreased after treatment,and tumor markers in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The inflammatory factors in the observation group were lower than those in the control group after treatment,and the difference was statistically significant(P<0.05).There was no statistical significance in adverse reactions between the two groups(P>0.05).Conclusion The combination of pyrrotinib,docetaxel and trastuzumab in the treatment of HER2-positive advanced breast cancer has good clinical efficacy,can effectively reduce tumor markers and inflammatory indicators,and has good safety.关键词
HER2阳性晚期乳腺癌/吡咯替尼/多西他赛/曲妥珠单抗/临床治疗效果/安全性Key words
HER2 positive advanced breast cancer/Pyrrolitinib/Docetaxel/Trastuzumab/Clinical therapeutic effect/Security分类
医药卫生引用本文复制引用
刘译婷,孙立柱,汤青,李伟,刘田田..吡咯替尼、多西他赛和曲妥珠单抗联合治疗HER2阳性晚期乳腺癌的临床效果及安全性评价[J].中国医药科学,2025,15(5):124-127,4.基金项目
江苏省卫生健康委科研项目(M2021096). （M2021096）
